Betibeglogene autotemcel

Therapeutic indications

Betibeglogene autotemcel is indicated for:

Transfusion-dependent β-thalassaemia (TDT) without β⁰/β⁰ genotype

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Betibeglogene autotemcel is indicated for the treatment of patients 12 years and older with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Betibeglogene autotemcel is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

HIV-1, HIV-2

at least one of
Human immunodeficiency virus I infection
Human immunodeficiency virus II infection

Anti-retroviral medications, hydroxyurea

at least one of
Nucleoside and nucleotide reverse transcriptase inhibitors
Hydroxycarbamide
Antivirals for treatment of HIV infections, combinations

Iron chelators

at least one of
Deferoxamine
Deferiprone
Deferasirox

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: ZYNTEGLO Dispersion for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈